Safety and Efficacy of J147 in Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 196 participants.

Also called NCT07430917

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 196 participants (planned count) (from the registry)
Sponsor
Abrexa Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT07430917
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07430917. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-22 (actual); primary completion 2028-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of J147 in Acute Ischemic Stroke
Acronym
JUMPSTART
Condition
Acute Ischemic Stroke
Intervention (Drug)
J147 Emulsion for Injection
Intervention (Other)
Placebo
Lead sponsor
Abrexa Pharmaceuticals, Inc. (class: industry)
Collaborator
IQVIA RDS Inc. (class: industry)

Record details

Record id
cardio:ct-nct07430917
Content hash
ad2e7903374e1e8f752c86d8bef7a2ac5bb83760b17318220c076d69ea5ea769